MDPI and ACS Style
Wußmann, M.; Groeber-Becker, F.K.; Riedl, S.; Alihodzic, D.; Padaric, D.; Gerlitz, L.; Stallinger, A.; Liegl-Atzwanger, B.; Zweytick, D.; Rinner, B.
In Model, In Vitro and In Vivo Killing Efficacy of Antitumor Peptide RDP22 on MUG-Mel2, a Patient Derived Cell Line of an Aggressive Melanoma Metastasis. Biomedicines 2022, 10, 2961.
https://doi.org/10.3390/biomedicines10112961
AMA Style
Wußmann M, Groeber-Becker FK, Riedl S, Alihodzic D, Padaric D, Gerlitz L, Stallinger A, Liegl-Atzwanger B, Zweytick D, Rinner B.
In Model, In Vitro and In Vivo Killing Efficacy of Antitumor Peptide RDP22 on MUG-Mel2, a Patient Derived Cell Line of an Aggressive Melanoma Metastasis. Biomedicines. 2022; 10(11):2961.
https://doi.org/10.3390/biomedicines10112961
Chicago/Turabian Style
Wußmann, Maximiliane, Florian Kai Groeber-Becker, Sabrina Riedl, Dina Alihodzic, Daniel Padaric, Lisa Gerlitz, Alexander Stallinger, Bernadette Liegl-Atzwanger, Dagmar Zweytick, and Beate Rinner.
2022. "In Model, In Vitro and In Vivo Killing Efficacy of Antitumor Peptide RDP22 on MUG-Mel2, a Patient Derived Cell Line of an Aggressive Melanoma Metastasis" Biomedicines 10, no. 11: 2961.
https://doi.org/10.3390/biomedicines10112961